Precision medicine in pediatric oncology

Purpose of review The current review describes recent advances and unique challenges in precision medicine for pediatric cancers and highlights clinical trials assessing the clinical impact of targeted therapy matched to molecular alterations identified by tumor profiling. Recent findings Multiple prospective clinical sequencing studies in pediatric oncology have been reported in the last 2 years. These studies demonstrated feasibility of sequencing in the clinic and revealed a rate of actionable variants that justifies the development of precision trials for childhood cancer. A number of precision medicine trials are recently completed, underway or in development and these will be reviewed herein, with a focus on highlighting aspects of precision medicine trial design relevant to pediatric oncology. Summary The primary results of the first round of pediatric precision oncology clinical trials will provide us with a greater understanding of the clinical impact of linking tumor profiling to selection of targeted therapies. The aggregation of sequencing and clinical data from these trials and the results of biologic investigations linked to these trials will drive further discoveries and broaden opportunities for precision medicine for children with cancer.

[1]  Sven Rahmann,et al.  Mutational dynamics between primary and relapse neuroblastomas , 2015, Nature Genetics.

[2]  Toshihiro Kumabe,et al.  Cytogenetic prognostication within medulloblastoma subgroups. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[4]  Qing-Rong Chen,et al.  A Children's Oncology Group and TARGET Initiative Exploring the Genetic Landscape of Wilms Tumor , 2017, Nature Genetics.

[5]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[6]  Li Ding,et al.  The Pediatric Cancer Genome Project , 2012, Nature Genetics.

[7]  Gudrun Schleiermacher,et al.  Implementation of mechanism of action biology-driven early drug development for children with cancer. , 2016, European journal of cancer.

[8]  Stuart J. Andrews,et al.  Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations , 2016, Genome Medicine.

[9]  B. Crompton,et al.  Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. , 2016, JAMA oncology.

[10]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[11]  Steven J. M. Jones,et al.  Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. , 2016, Cancer cell.

[12]  Jonathan M Marron,et al.  Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience , 2016, Pediatric blood & cancer.

[13]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[14]  P. Raman,et al.  Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome , 2016, PLoS genetics.

[15]  Gudrun Schleiermacher,et al.  Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.

[16]  G. Caponigro,et al.  Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma , 2016, Clinical Cancer Research.

[17]  J. Biegel,et al.  Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. , 2010, Neuro-oncology.

[18]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[19]  Caroline McNeil,et al.  NCI-MATCH launch highlights new trial design in precision-medicine era. , 2015, Journal of the National Cancer Institute.

[20]  Nallasivam Palanisamy,et al.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.

[21]  M. Schrappe,et al.  Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. , 2015, European journal of cancer.

[22]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[23]  A. Chinnaiyan,et al.  Precision medicine in pediatric oncology: Lessons learned and next steps , 2017, Pediatric blood & cancer.

[24]  M. Harris,et al.  Future of clinical genomics in pediatric oncology. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Roland Eils,et al.  The whole-genome landscape of medulloblastoma subtypes , 2017, Nature.

[26]  P. Nathan,et al.  Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. , 2016, The New England journal of medicine.

[27]  M. Lim,et al.  Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial , 2017, Journal of the National Cancer Institute.

[28]  S. Hunger,et al.  Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics , 2017, British journal of haematology.

[29]  C. Mullighan,et al.  Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. , 2017, Blood.

[30]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[31]  F. Speleman,et al.  Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Reaman,et al.  Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents , 2016, Clinical Cancer Research.

[33]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[34]  Edward S. Kim,et al.  Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[36]  P. Varlet,et al.  Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial , 2017, Clinical Cancer Research.

[37]  M. Loh,et al.  Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2017, Blood.

[38]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[39]  M. Konopleva,et al.  Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. , 2017, Clinical advances in hematology & oncology : H&O.

[40]  Yoon-Jae Cho,et al.  Pediatric oncology enters an era of precision medicine. , 2017, Current problems in cancer.

[41]  S. Pfister,et al.  Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective , 2017, Nature Reviews Clinical Oncology.

[42]  Lisa McShane,et al.  National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[43]  Sumithra J Mandrekar,et al.  Precision oncology: A new era of cancer clinical trials. , 2017, Cancer letters.

[44]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[45]  M. Loh,et al.  Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies , 2017, Clinical Cancer Research.

[46]  O. Delattre,et al.  Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors , 2017, Pediatric blood & cancer.

[47]  M. Loh,et al.  Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. , 2013, Blood.

[48]  A. Chen,et al.  Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. , 2017, Current problems in cancer.

[49]  K. Janeway Molecular profiling in the clinic: Moving from feasibility assessment to evaluating clinical impact , 2017, Pediatric blood & cancer.

[50]  Asher Mullard,et al.  NCI-MATCH trial pushes cancer umbrella trial paradigm , 2015, Nature Reviews Drug Discovery.